Plain-English translation of NCT07096193 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1/2 β A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a clinical trial testing a new medication called for people with chronic hepatitis delta, a serious liver infection. The study has two parts: first, researchers give healthy volunteers small amounts of the medication to understand how it works and check for side effects; then, people with hepatitis delta receive the medication over several months to see if it actually helps fight the infection.
Hepatitis delta is a rare but serious liver disease that affects people already infected with hepatitis B, and there are limited treatment options available. This trial aims to discover whether this new treatment can safely reduce or eliminate the virus.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you qualify for the healthy volunteer part (Phase 1), you will receive a single dose of the medication or placebo and be monitored for safety. If you have hepatitis delta (Phase 2), you will take increasing doses of the medication over up to 96 weeks (about 2 years) while researchers monitor how well it works, check for side effects, and take blood samples to measure your viral levels and liver function.
AI-generated summary from trial data Β· Jun 12, 2026 Β· Not medical advice
United States
Bulgaria